HighTower Advisors LLC Has $5.83 Million Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) – Ticker Report
Other hedge funds and other institutional investors also recently modified their holdings of the company. Artisan Partners Limited Partnership lifted its position in shares of NeoGenomics by 43.1% in the third quarter. Artisan Partners Limited Partnership now owns 6,931,041 shares of the medical research company’s stock valued at $334,353,000 after buying an additional 2,086,662 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of NeoGenomics by 36.7% in the third quarter. Wellington Management Group LLP now owns 7,585,848 shares of the medical research company’s stock valued at $365,942,000 after buying an additional 2,037,787 shares during the last quarter. Macquarie Group Ltd. lifted its position in shares of NeoGenomics by 134.3% in the third quarter. Macquarie Group Ltd. now owns 2,042,456 shares of the medical research company’s stock valued at $98,528,000 after buying an additional 1,170,745 shares during the last quarter. Schroder Investment Management Group acquired a new stake in shares of NeoGenomics in the third quarter valued at approximately $48,625,000. Finally, Brown Advisory Inc. lifted its position in shares of NeoGenomics by 10.9% in the fourth quarter. Brown Advisory Inc. now owns 3,716,012 shares of the medical research company’s stock valued at $126,791,000 after buying an additional 366,464 shares during the last quarter. 95.03% of the stock is owned by hedge funds and other institutional investors.
NeoGenomics stock opened at $8.91 on Tuesday. The stock’s fifty day moving average price is $12.84 and its two-hundred day moving average price is $23.72. NeoGenomics, Inc. has a one year low of $7.26 and a one year high of $54.74. The company has a debt-to-equity ratio of 0.50, a current ratio of 7.93 and a quick ratio of 7.64. The firm has a market cap of $1.11 billion, a PE ratio of -27.84 and a beta of 0.86.
NeoGenomics (NASDAQ:NEO – Get Rating) last issued its quarterly earnings results on Wednesday, April 27th. The medical research company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.04. NeoGenomics had a negative return on equity of 6.62% and a negative net margin of 7.33%. The company had revenue of $117.17 million for the quarter, compared to analyst estimates of $116.44 million. During the same quarter last year, the company posted ($0.06) EPS. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Sell-side analysts expect that NeoGenomics, Inc. will post -0.98 earnings per share for the current fiscal year.
In other news, CFO William Bonello sold 3,209 shares of NeoGenomics stock in a transaction on Monday, March 7th. The stock was sold at an average price of $18.29, for a total value of $58,692.61. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 1.00% of the company’s stock.
NEO has been the topic of a number of recent research reports. Stephens lowered NeoGenomics from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $34.00 to $16.00 in a research note on Tuesday, March 29th. Raymond James lowered their target price on NeoGenomics from $24.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, April 18th. Morgan Stanley lowered their target price on NeoGenomics from $29.00 to $27.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 12th. BTIG Research lowered their target price on NeoGenomics from $35.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, March 29th. Finally, Zacks Investment Research lowered NeoGenomics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $24.64.
About NeoGenomics (Get Rating)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.
Recommended Stories
- Get a free copy of the StockNews.com research report on NeoGenomics (NEO)
- Etsy Buy!: Why Etsy Stock is Making a Crafty Comeback
- FIGS, Inc Moves Lower On Analysts’ Downgrades
- MarketBeat Podcast: Trading Volatile Markets While Preserving Capital
- Option Care Health Stock is Making a Healthy Pullback
- Warby Parker Stock Is A High-Probability Candidate For A Short-Squeeze
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO – Get Rating).
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source